We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
治疗药物监测下奈玛特韦片 / 利托那韦片组合 包装与伏立康唑的联合应用.
- Authors
陈 玥; 郭冬杰; 李少强; 陈文倩; 王晓星; 陈 玮; 孔旭东; 李朋梅; 刘丽宏
- Abstract
OBJECTIVE: To investigate whether Nematavir tablet / Ritonavir tablet ( co-packaged) ( hereinafter referred to as “ nematavir/ ritonavir ”) in combination with voriconazole would affect voriconazole exposure. METHODS: Patients who were concurrently treated with voriconazole and nirmatrelvir/ ritonavir during the COVID-19 outbreak in Beijing from Dec. 2022 to Jan. 2023 at the National Center for Respiratory Medicine were retrospectively enrolled. Dosage, drug combination, voriconazole concentration and adverse drug reactions were recorded and analyzed. RESULTS: A total of 17 voriconazole concentrations of 14 patients were included. Only 1 patient had low blood drug concentration, 2 patients exceeded 50% of the upper limit of treatment, most patients were within the therapeutic range. Among the 7 patients with baseline voriconazole concentration data, all but 1 patient’ voriconazole concentration was similar to or slightly higher than the baseline concentration. Compared with other data of voriconazole concentration, the proportion of higher voriconazole concentration was slightly increased in the combined one. No adverse drug reactions attributable to the two drugs were found. CONCLUSIONS: Different from the instructions, the combined use of voriconazole and nirmatrelvir/ ritonavir is feasible in Chinese population. Therapeutic drug monitoring is recommended to ensure safety and effectiveness.
- Subjects
BEIJING (China); DRUG side effects; DRUG monitoring; COVID-19 pandemic; VORICONAZOLE; CHINESE people
- Publication
Evaluation & Analysis of Drug-Use in Hospitals of China, 2023, Vol 23, Issue 8, p913
- ISSN
1672-2124
- Publication type
Article
- DOI
10.14009/j.issn.1672-2124.2023.08.004